Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up
Posted inClinical Updates Hematology-Oncology Specialties Wellness & Lifestyle

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.
Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Posted inHematology-Oncology Specialties

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell lymphoma with a favorable safety profile.